QLGNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system...

Stats
本日の出来高	9 087.00
平均出来高	65 834.00
時価総額	1.83M
EPS	$-0.640 ( 2023-11-14 )
次の収益日	( $-0.520 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.00700 (2.41%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-11	Abdul-ahad Wajdi	Buy	80 000	Stock Option (Right to Buy)
2022-07-11	Lotz Christopher L.	Buy	100 000	Stock Option (Right to Buy)
2022-07-11	Lotz Christopher L.	Buy	100 000	Stock Option (Right to Buy)
2022-07-11	Arshad Tariq	Buy	102 000	Stock Option (Right to Buy)
2022-07-11	Ritter Ira E.	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 89 transactions
Buy: 8 588 032 \| Sell: 1 076 061

Qualigen Therapeutics Inc 相関

10 最も正の相関
LYEL	0.959
ARQQ	0.958
WISA	0.956
FATE	0.954
QTEK	0.953
RPID	0.953
STRC	0.951
NKTX	0.951
LYRA	0.945
GROM	0.944

10 最も負の相関
LRFC	-0.955
NWFL	-0.954
STAY	-0.944
LUNA	-0.941
TIPT	-0.939
IBEX	-0.938
IVAC	-0.936
PEBK	-0.935
GLLI	-0.931
CCRC	-0.931

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Qualigen Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-4 495.00 (0.00 %)
EPS:	$-2.53

FY	2023
収益:	$0
総利益:	$-4 495.00 (0.00 %)
EPS:	$-2.53

FY	2022
収益:	$4.98M
総利益:	$680 801 (13.66 %)
EPS:	$-5.48

FY	2021
収益:	$5.65M
総利益:	$1.32M (23.37 %)
EPS:	$-6.10

Financial Reports:

No articles found.

Qualigen Therapeutics Inc

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.